Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
Public ClinicalTrials.gov record NCT05041257. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Study identification
- NCT ID
- NCT05041257
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Interventions
- Mirvetuximab soravtansine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 18, 2021
- Primary completion
- Dec 11, 2024
- Completion
- Dec 11, 2024
- Last update posted
- Jan 8, 2026
2021 – 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center /ID# 269928 | Duarte | California | 91010 | — |
| University of California Los Angeles /ID# 269969 | Los Angeles | California | 90095-3075 | — |
| University Colorado Cancer Center /ID# 269930 | Aurora | Colorado | 80045-2517 | — |
| Women'S Cancer Care /ID# 269925 | Covington | Louisiana | 70433 | — |
| Holy Name Medical Center /ID# 269927 | Teaneck | New Jersey | 07666 | — |
| Cleveland Clinic Main Campus /ID# 269922 | Cleveland | Ohio | 44195 | — |
| The Mark H Zangmeister Center /ID# 269929 | Columbus | Ohio | 43219 | — |
| Women & Infants Hospital /ID# 269923 | Providence | Rhode Island | 02905 | — |
| Duplicate_SCRI - Tennessee Oncology /ID# 269921 | Nashville | Tennessee | 37203-1632 | — |
| Texas Oncology - South Austin /ID# 269924 | Austin | Texas | 78745 | — |
| Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 269926 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05041257, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05041257 live on ClinicalTrials.gov.